Is Australian HealthTech having a renaissance moment? Mostly yes, with a caveat that matters. In nine months Australia has produced a US$1.15 billion healthtech sale, a US$900 million AI scribe and a string of large rounds, but the new wave is also being tested by scale, regulation and the pull of the US market.

The successful closure of Blackbird Ventures' Fund VI at A$1.05 billion represents a critical structural milestone in the maturation of the Australia and New Zealand (ANZ) private capital markets. Marginally exceeding its A$1.035 billion predecessor from 2022, the vehicle stands as the largest single venture capital fund raised in the region's history. Beyond its absolute capital magnitude, the composition of the fund’s Limited Partner (LP) base signals a structural shift in